S K AGE Exports — Erythromycin Exporter Profile
Indian Pharmaceutical Exporter · #13 for Erythromycin · $1.1M export value · DGFT Verified
S K AGE Exports is the #13 Indian exporter of Erythromycin with $1.1M in export value and 54 verified shipments. S K AGE Exports holds a 1.4% market share in Erythromycin exports across 7 countries. The company exports 9 pharmaceutical products worth $25.0M across 5 therapeutic categories.
S K AGE Exports — Erythromycin Export Profile: Buyers & Destinations
Where Does S K AGE Exports Export Erythromycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| PAKISTAN | $780.8K | 17 | 22.5% |
| NETHERLANDS | $729.2K | 36 | 21.0% |
| UNITED ARAB EMIRATES | $575.1K | 35 | 16.6% |
| TANZANIA | $462.9K | 17 | 13.3% |
| DENMARK | $224.6K | 8 | 6.5% |
| SINGAPORE | $122.1K | 7 | 3.5% |
| BURKINA FASO | $96.1K | 5 | 2.8% |
| CONGO, THE DEMOCRATIC REPUBLIC OF THE | $90.6K | 3 | 2.6% |
| CONGO | $66.2K | 4 | 1.9% |
| AFGHANISTAN | $50.0K | 1 | 1.4% |
S K AGE Exports exports Erythromycin to 23 countries. The largest destination is PAKISTAN accounting for 22.5% of S K AGE Exports's Erythromycin shipments, followed by NETHERLANDS (21.0%) and UNITED ARAB EMIRATES (16.6%). These destinations reflect S K AGE Exports's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Erythromycin from S K AGE Exports?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TO THE ORDER | NETHERLANDS | $3.3M | 139 |
| ERRA | NETHERLANDS | $88.7K | 5 |
| TO THE ORDER. | HAITI | $14.4K | 1 |
S K AGE Exports supplies Erythromycin to 3 buyers globally. The largest buyer is TO THE ORDER (NETHERLANDS), followed by ERRA (NETHERLANDS) and TO THE ORDER. (HAITI). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Erythromycin Export Value and How Much Does S K AGE Exports Contribute?
India exported $19.0M worth of Erythromycin through 3,939 shipments from 368 suppliers to 135 countries, serving 992 buyers globally. S K AGE Exports contributes $1.1M to this total, accounting for 1.4% of India's Erythromycin exports. S K AGE Exports ships Erythromycin to 23 countries through 3 buyers.
What Is the Average Shipment Value for S K AGE Exports's Erythromycin Exports?
S K AGE Exports's average Erythromycin shipment value is $20.8K per consignment, based on 54 shipments totaling $1.1M. The largest destination is PAKISTAN (22.5% of S K AGE Exports's Erythromycin exports).
How Does S K AGE Exports Compare to Other Indian Erythromycin Exporters?
S K AGE Exports ranks #13 among 368 Indian Erythromycin exporters with a 1.4% market share. The top 3 exporters are MEDOPHARM ($3.0M), S KANT HEALTHCARE LIMITED ($2.8M), MEDREICH LIMITED ($2.1M). S K AGE Exports processed 54 shipments to 7 destination countries.
What Erythromycin Formulations Does S K AGE Exports Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| HARMLESS MEDICINE-ERYTHROMYCIN STEARATE | $488.1K | 15 |
| HARMLESS MEDICINES-ERYTHROMYCIN ETHYL SU | $406.2K | 16 |
| HARMLESS MEDICINE-ERYTHROMYCIN ETHYL SUC | $379.9K | 25 |
| HARMLESS MEDICINES-ERYTHROMYCIN ETHYL SUCCINATE ORAL SUSPENSION BP 125MG/5ML UNIT:100 MLNOS | $361.7K | 9 |
| HARMLESS MEDICINE - ERYTHROMYCIN ETHYL SUCCINATE ORAL SUSPENSION BP 125MG/5ML Unit : 100 ml | $314.6K | 8 |
| HARMLESS MEDICINES-ERYTHROMYCIN ETHYL SUCCINATE ORAL SUSPENSION BP 125MG/5ML UNIT:100 ML | $143.9K | 3 |
| HARMLESS MEDICINES-ERYTHROMYCIN ETHYL SUCCINATE ORAL SUSPENSION BP 125MG/5ML Unit : 100 ml | $88.3K | 2 |
| HARMLESS MEDICINE ERYTHROMYCIN STEARATE TABLETS BP 250 MG F C Unit 100x10 Tab | $84.2K | 3 |
| HARMLESS MEDICINE -ERYTHROMYCIN ETHYL SUCCINATE ORAL SUSPENSION BP 125MG/5ML Unit : 100 ml | $80.8K | 2 |
| HARMLESS MEDICINE - ERYTHROMYCIN ETHYL SUCCINATE ORAL SUSPENSION BP 125MG/5ML Unit : 100ml | $68.7K | 3 |
S K AGE Exports exports 55 distinct Erythromycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is HARMLESS MEDICINE-ERYTHROMYCIN STEARATE with 15 shipments worth $488.1K.
How Does S K AGE Exports Compare to Nearest Erythromycin Exporters?
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 10 | ANGEL BIOGENICS PRIVATE LIMITED | $1.2M | 28 | 2 | $44.6K |
| 11 | CAPLIN POINT LABORATORIES LIMITED | $1.2M | 24 | 4 | $50.0K |
| 13 | S K AGE EXPORTS ★ | $1.1M | 54 | 7 | $20.8K |
| 2 | BDH INDUSTRIES LIMITED | $850.0K | 17 | 7 | $50.0K |
| 12 | SIDHAANT LIFE SCIENCES PRIVATE LIMITED | $750.0K | 15 | 6 | $50.0K |
S K AGE Exports ranks #13 among 368 Indian Erythromycin exporters. Average shipment value of $20.8K compared to the market average of $51.7K. The closest competitors by value are ANGEL BIOGENICS PRIVATE LIMITED and CAPLIN POINT LABORATORIES LIMITED.
Which Indian Ports Ship Erythromycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 513 | 13.0% |
| DELHI AIR CARGO ACC (INDEL4) | 394 | 10.0% |
| SAHAR AIR | 377 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 370 | 9.4% |
| JNPT/ NHAVA SHEVA SEA | 234 | 5.9% |
| DELHI AIR | 227 | 5.8% |
| JNPT | 176 | 4.5% |
| Bombay Air | 99 | 2.5% |
What Other Antibiotics Products Does S K AGE Exports Export?
S K AGE Exports also exports these antibiotics products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on S K AGE Exports's Erythromycin Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like S K AGE Exports. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased shipping costs and extended transit times. These disruptions have resulted in freight inflation, with transport charges doubling and surcharges ranging from $4,000 to $8,000 per shipment. (pharmaceuticalcommerce.com) Such logistical challenges can impact the timely delivery of pharmaceuticals, particularly to markets in the Middle East and North Africa.
Conversely, US-China trade tensions have prompted the United States to seek alternative sources for pharmaceuticals, potentially benefiting Indian exporters. India supplies 47% of the US's generic drugs, underscoring its critical role in the American healthcare system. (orfonline.org) However, the imposition of tariffs on Indian pharmaceutical products by the US poses a risk, potentially leading to reduced export volumes and increased compliance costs. (transdatanexus.com)
In the European Union, the implementation of the Falsified Medicines Directive (FMD) necessitates stringent compliance measures. Indian exporters must ensure adherence to these regulations to maintain market access. The India–EFTA Trade and Economic Partnership Agreement, effective from October 1, 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially enhancing market opportunities for exporters like S K AGE Exports. (en.wikipedia.org)
S K AGE Exports — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. India has made significant strides in this area, with 752 FDA-approved, 2,050 WHO GMP-certified, and 286 EDQM-approved manufacturing facilities as of 2024. (ibef.org) Instances of non-compliance have decreased, indicating improved adherence to quality standards. For S K AGE Exports, maintaining such compliance is essential to ensure uninterrupted market access and to uphold the company's reputation in the global pharmaceutical industry.
About S K AGE Exports
S K AGE Exports exports 9 products worth $25.0M. Beyond Erythromycin, top products include Artemether, Clotrimazole, Gentamicin, Sulfadoxine, Pyrimethamine. View the complete S K AGE Exports profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Erythromycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Erythromycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: S K AGE Exports matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 149 individual customs records matching S K AGE Exports exporting Erythromycin, covering 55 formulations to 23 countries via 3 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 135+ countries, 992+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Erythromycin Export Data from S K AGE Exports
Access shipment-level details, pricing data, buyer connections, and competitive analysis for S K AGE Exports's Erythromycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
S K AGE Exports
Full Company Profile →
9 products · $25.0M total trade · 5 categories
Erythromycin Stats
Company Overview
Top Products by S K AGE Exports
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for S K AGE Exports.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Erythromycin. For current shipment-level data, contact TransData Nexus.